Recent Updates
Recently added Catalysts

PF-06669571

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Jul 24, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment56

FDA Designations

No designations recorded

Clinical trial landscape

PF-06669571 · 2 trials · 2 indications

Phase 1 2
NCT02565628PF-06669571 In Subjects With Idiopathic Parkinson's DiseaseIdiopathic Parkinson's Disease
COMPLETED20 Analytics
NCT02184429A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed ConditionsHealthy
COMPLETED56 Analytics
PHASE1COMPLETED
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
Idiopathic Parkinson's DiseaseUnlock trial analytics
PHASE1COMPLETED
A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Maximum Percent Change From Baseline in Movement Disorder Society-Sponsor Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Day 7.
Day 7

The total MDS-UPDRS score is the most common method of evaluating the severity of Parkinson's disease across behaviors, activities of daily living, motor abilities, and other complications of Parkinson's disease. The MDS-UPDRS focuses primarily on measuring impairments associated with Parkinson's disease, with subsections organized according to motor and non-motor aspects of the disease. Part III assesses the motor signs of Parkinson's disease. Higher total scores indicate more severe motor signs of Parkinson's disease. Negative changes from baseline indicate improvement. MDS-UPDRS Part III total motor score is comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question is anchored with five responses that are linked to commonly accepted clinical terms: 0 = normal, 1 = slight, 2 = mild, 3 = moderate and 4 = severe.

Number of Participants in Each Columbia Classification Algorithm of Suicide Assessment (C-CASA) Category by Study Visit on Day -2, Day 8 or Early Withdrawal, and Early Withdrawal/Follow-Up Visit
Day -2, Day 8, and follow-up visit (Day 7 - 14 after last dose of PF-06669571)

The number of participants in each C-CASA category was mapped from Columbia-Suicide Severity Rating Scale (C-SSRS) data. C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) ("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act or some intent to act, with specific plan and intent"), any suicidal behavior or ideation, self-injurious behavior (7) ("Yes" on "Has subject engaged in non-suicidal self-injurious behavior").

Number of Participants With New Onset and Worsening of Post-Baseline Suicidality.
Day 8 or follow-up visit (Day 7 - 14 after last dose of PF-06669571)

Number of participants with new onset and worsening of post-baseline suicidality was reported

Number of Participants With Treatment Emergent Adverse Events (All Causalities)
Day 1 to 28 calendar days after the last dose of investigational product

An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

Number of Participants With Supine and Standing Vital Sign Abnormalities of Potential Clinical Concern (Absolute Values)
Screening, Days -1, 1, 7 and 8, and follow-up visit

Number of participants with supine and standing vital signs data of absolute values meeting criteria of potential clinical concern. Absolute values were analyzed for supine/standing systolic blood pressure (SBP), supine/standing diastolic blood pressure (DBP), and supine/standing pulse rate. Number of participants with vital signs data meeting the following criteria was reported: (1) absolute supine SBP \<90 millimeters of mercury (mmHg); (2) absolute standing SBP \<90 mmHg; (3)absolute supine DBP\<50mmHg; (4)absolute standing DBP\<50mmHg (5) absolute supine pulse rate \<40 beats per minute (bpm); (6) absolute supine pulse rate \>120 bpm;(7) absolute standing pulse rate \<40 bpm; (8) absolute standing pulse rate \>140 bpm.

Number of Participants With Supine and Standing Vital Sign Abnormalities of Potential Clinical Concern (Increase From Baseline)
Screening, Days -1, 1, 7 and 8, and follow-up visit

The number of participants with vital signs data of maximum increase from baseline meeting the following criteria was reported: Criterion A: maximum increase from baseline in supine systolic BP (SBP) \>=30 millimeters of mercury (mmHg); Criterion B maximum increase from baseline in standing SBP \>=30 mmHg; Criterion C: maximum increase from baseline in supine diastolic BP(DBP) \>=20 mmHg; Criterion D: maximum increase from baseline in standing diastolic BP(DBP) \>=20 mmHg

Number of Participants With Supine and Standing Vital Sign Abnormalities (Decrease From Baseline)
Screening, Days -1, 1, 7 and 8, and follow-up visit

The number of participants with vital signs data of maximum decrease from baseline meeting the following criteria was reported: Criterion A: maximum decrease from baseline in supine systolic BP (SBP) \>=30 mmHg; Criterion B: maximum decrease from baseline in standing SBP \>=30 mmHg; Criterion C: maximum decrease from baseline in supine diastolic BP(DBP) \>=20 mmHg; Criterion D: maximum decrease from baseline in standing diastolic BP(DBP) \>=20 mmHg

Number of Participants With Electrocardiogram (ECG) That Met Categorical Criteria for Concern (Absolute Value)
Screening, Days 1, 7, and 8, and follow-up visit

The number of participants with ECG absolute values meeting the following criteria was reported: Criterion A: maximum PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization) \>=300 msec; Criterion B: maximum QRs complex(time from Q wave to the end of S wave, corresponding to ventricle depolarization) \>=140 msec; Criterion C: maximum QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole, corrected for heart rate using Fridericia's formula) 450-\<480 msec; Criterion D: maximum QTcF interval 480-\<500 msec; Criterion E: maximum QTcF interval (Fridericia's correction) \>=500 msec

Primary: Number of Participants With Electrocardiogram (ECG) That Met Categorical Criteria for Concern(Increase From Baseline)
Screening, Days 1, 7, and 8, and follow-up visit

Number of participants with ECG(standard 12-lead) meeting the following criteria was reported: Criterion A: maximum PR interval increase from baseline percentage change (PctChg)\>=25/50%; Criterion B: maximum QRs complex increase from baseline PctChg \>=50%; Criterion C: maximum QTcF interval increase from baseline 30\<=change\<60 msec; Criterion D: maximum QTcF interval increase from baseline change \>=60 msec.

Number of Participants With Laboratory Abnormalities That Met Categorical Criteria for Concern (Without Regard to Baseline Abnormality)
Screening, Days 1, 4, and 7, and follow-up visit

Number of participants with a laboratory abnormality meeting specified criteria. The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, absolute eosinophils, absolute basophils, absolute monocytes, and absolute lymphocytes),liver function(total bilirubin, direct bilirubin, aspartate, aspartate aminotransferase, alanine, alanine aminotransferase, alkaline phosphatase, total protein, and albumin), renal function (blood urea nitrogen, creatinine, and uric acid), electrolytes (sodium, potassium, chloride, calcium, and venous bicarbonate), clinical chemistry(glucose) ,and urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, qualitative ketones, qualitative bilirubin, nitrites, leukocyte esterase, urine urobilinogen, urine leukocyte, esterase and microscopy).

Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
screening,Day 28

C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3)("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior").

Secondary Endpoints

Maximum Observed Plasma Concentration (Cmax) of PF-06669571 on Day 1 and Day 7
0, 1, 3, 5, 8 and 12 hours post-dose on both Day 1 and Day 7
Area Under Curve From Time Zero to 12 Hours (AUC12) of PF-06669571 on Day 1 and Day 7
0, 1, 3, 5, 8 and 12 hours post-dose on both Day 1 and Day 7
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06669571 on Day 1 and Day 7
0, 1, 3, 5, 8 and 12 hours post-dose on both Day 1 and Day 7
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
PF-06669571EXPERIMENTALOnce daily (QD) for 7 days
PlaceboPLACEBO_COMPARATORQD for 7 days
Single Ascending Dose-1EXPERIMENTALSingle ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
Single Ascending Dose-2EXPERIMENTALSingle ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
Multiple Ascending Dose-1EXPERIMENTALDaily dose of PF-06669571 in healthy volunteers
Multiple Ascending Dose-2EXPERIMENTALDaily dose of PF-06669571 in healthy volunteers
Multiple Ascending Dose-3EXPERIMENTALDaily dose of PF-06669571 in healthy volunteers
Multiple Ascending Dose-4EXPERIMENTALDaily dose of PF-06669571 in healthy volunteers
Multiple Ascending Dose-5EXPERIMENTALDaily dose of PF-06669571 in healthy volunteers

Interventions

NameTypeDescription
PF-06669571DRUG1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
PlaceboDRUGPlacebo
Unlock Study Design Details

Eligibility Criteria

Age Range45 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Subjects must have a clinical diagnosis of idiopathic Parkinson's disease and presence of at least 2 out of 3 cardinal characteristics (tremor, rigidity and/or bradykinesia). * Must be Hoehn \& Yahr Stage II-III inclusive and experiencing motor fluctuations in the form of end-...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about PF-06669571

What is PF-06669571 used for?

PF-06669571 is an investigational small molecule being studied for use in idiopathic Parkinson's disease. It has also been evaluated in healthy volunteers to understand its safety and plasma concentrations. The drug is in Phase 1 clinical development and is not approved by the FDA.

Who makes PF-06669571?

PF-06669571 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics.

What phase is PF-06669571 in?

PF-06669571 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in healthy volunteers and one in subjects with idiopathic Parkinson's disease. The drug remains investigational and has not received FDA approval.

What clinical trials is PF-06669571 in?

PF-06669571 has been studied in two completed Phase 1 trials. NCT02184429 evaluated safety and plasma concentrations in healthy volunteers under fasted and fed conditions. NCT02565628 studied the drug in subjects with idiopathic Parkinson's disease. Both trials were conducted in the United States.

Is PF-06669571 the same as any other drug?

PF-06669571 is the primary name for this investigational compound. No alternative names have been reported for this drug in clinical trial registrations. It is a small molecule being developed by Pfizer for potential use in Parkinson's disease.